← All trials
NCT06527222
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2024
- Primary completion
- Mar 31, 2025
- Completion date
- Dec 31, 2026
- First posted
- Jul 30, 2024
- Last posted
- Aug 14, 2024
- Enrollment
- 72
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of KansasLead sponsor
- University of KansasSponsor investigator
- ALS AssociationCollaborator
- University of KansasOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.